Radix Tetrastigma flavonoids inhibit the migration and promote the apoptosis of A549 cells both in vitro and in vivo
[Display omitted] •RTF exhibited excellent anti-tumor capacity both in vitro and in vivo.•RTF inhibited the invasion and migration of A549 via facilitating F-actin collapse.•RTF suppressed tumor growth via bax/bcl-2/caspase-9/caspase-3-dependent pathway.•RTF restrained VEGF expression and thereby su...
Gespeichert in:
Veröffentlicht in: | Journal of functional foods 2020-09, Vol.72, p.104076, Article 104076 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | [Display omitted]
•RTF exhibited excellent anti-tumor capacity both in vitro and in vivo.•RTF inhibited the invasion and migration of A549 via facilitating F-actin collapse.•RTF suppressed tumor growth via bax/bcl-2/caspase-9/caspase-3-dependent pathway.•RTF restrained VEGF expression and thereby suppressed angiogenesis in tumor.
The main flavonoid components of Radix Tetrastigma (RTF) were extracted and characterized by high performance liquid chromatography. In vitro, RTF suppressed the viability of A549 cells, and inhibited the invasion and migration of A549 by damaging the lamellipodium and the structure of F-actin. In vivo, compared to the model group, RTF inhibited the growth of tumor volumes in nude mice, and decreased the weight of tumor. To uncover the inner mechanism, the proliferation-related proteins: PCNA, Ki67 and the apoptosis-related proteins: caspase-3, caspase-9, Bax and Bcl-2 were examined by immunohistochemical and western blot analysis. Compared to the model group, the production levels of PCNA, Ki67 and Bcl-2 were significantly down-regulated by RTF, and the expression levels of caspase-3, caspase-9 and Bax were markedly up-regulated. Comprehensively, RTF could suppress the proliferation of A549 and promote the apoptosis of A549, suggesting RTF as a potential resource to fight against non-small cell lung cancer (NSCLC). |
---|---|
ISSN: | 1756-4646 2214-9414 |
DOI: | 10.1016/j.jff.2020.104076 |